MetLife Investment Management’s IGM Biosciences IGMS Stock Holding History

MetLife Investment Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,997	Closed	-$149K	–	2832
2024 Q3	$149K	Buy	+8,997	New	+$98.6K	﹤0.01%	2439
2024 Q2	–	Sell	-7,248	Closed	-$69.9K	–	2902
2024 Q1	$69.9K	Buy	+7,248	New	+$84K	﹤0.01%	2666
2023 Q2	–	Sell	-5,702	Closed	-$78.3K	–	2963
2023 Q1	$78.3K	Hold	5,702	–	–	﹤0.01%	2648
2022 Q4	$97K	Hold	5,702	–	–	﹤0.01%	2605
2022 Q3	$130K	Buy	5,702 +306	+6%	+$6.18K	﹤0.01%	2550
2022 Q2	$97.3K	Buy	+5,396	New	+$96.2K	﹤0.01%	2721
2022 Q1	–	Sell	-3,333	Closed	-$97.8K	–	2747
2021 Q4	$97.8K	Hold	3,333	–	–	﹤0.01%	2412
2021 Q3	$219K	Hold	3,333	–	–	﹤0.01%	2030
2021 Q2	$277K	Hold	3,333	–	–	﹤0.01%	1939
2021 Q1	$256K	Hold	3,333	–	–	﹤0.01%	1915
2020 Q4	$294K	Hold	3,333	–	–	﹤0.01%	1781
2020 Q3	$246K	Hold	3,333	–	–	﹤0.01%	1732
2020 Q2	$243K	Buy	3,333 +896	+37%	+$54.4K	﹤0.01%	1785
2020 Q1	$137K	Buy	+2,437	New	+$107K	﹤0.01%	1900

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's IGMS Position: Q4 2024 in Review

MetLife Investment Management sold out of IGM Biosciences (IGMS) in Q4 2024, closing a stake of 8,997 shares — an estimated $149K sold.

MetLife Investment Management first reported a position in IGMS in Q1 2020 and held it in 14 quarters. The position peaked at $294K in Q4 2020. 85 funds tracked by Wall St. Rank hold IGMS as of Q4 2024.

MetLife Investment Management reported no remaining IGM Biosciences position as of Q4 2024 after selling out during the quarter.
MetLife Investment Management sold 8,997 IGM Biosciences shares in Q4 2024, an estimated $149K.
MetLife Investment Management first reported a position in IGM Biosciences in Q1 2020 and held it in 14 quarters.
MetLife Investment Management's IGM Biosciences position peaked at $294K in Q4 2020.
85 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.